40,000 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 40,000 shares of the company's stock, valued at approximately $473,000.

Several other institutional investors have also added to or reduced their stakes in the stock. FMR LLC raised its position in Roivant Sciences by 0.3% in the 4th quarter. FMR LLC now owns 49,301,583 shares of the company's stock valued at $583,238,000 after buying an additional 156,527 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after purchasing an additional 2,404,232 shares during the last quarter. Patient Square Capital LP raised its holdings in shares of Roivant Sciences by 2.1% in the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock valued at $147,638,000 after purchasing an additional 251,535 shares during the last quarter. Two Seas Capital LP lifted its position in shares of Roivant Sciences by 4.6% in the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock worth $120,285,000 after purchasing an additional 442,914 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after purchasing an additional 3,159,603 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ROIV. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, May 28th. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.

Insider Activity at Roivant Sciences

In related news, major shareholder Vivek Ramaswamy sold 273,959 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares in the company, valued at $456,501,538.17. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Eric Venker sold 434,478 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the completion of the sale, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at approximately $12,197,277.80. The trade was a 27.82% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,223,959 shares of company stock valued at $24,604,977 in the last quarter. Insiders own 7.90% of the company's stock.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV traded down $0.03 during midday trading on Wednesday, reaching $11.21. The company's stock had a trading volume of 5,089,654 shares, compared to its average volume of 5,553,324. The company has a market cap of $8.00 billion, a P/E ratio of -74.73 and a beta of 1.23. The business's 50 day moving average price is $10.59 and its two-hundred day moving average price is $11.02. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The firm had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. During the same period in the prior year, the business earned ($0.23) earnings per share. Sell-side analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.